Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates
Rigel Reports First Quarter 2026 Financial Results
Rigel Pharmaceuticals (RIGL) to Report Q1 Results: Wall Street Expects Earnings Growth
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
Is the Options Market Predicting a Spike in Rigel Pharmaceuticals Stock?
Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (Rating Upgrade)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of “Moderate Buy” from Brokerages
Rigel Pharmaceuticals: Growing Where It Matters
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy?
IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?
Beacon Harbor Wealth Advisors Inc. Makes New $4.31 Million Investment in Rigel Pharmaceuticals, Inc. $RIGL
Rigel Appoints Michael P. Miller to the Board of Directors
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?
Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026
Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Rigel Provides Business Update and 2026 Outlook
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference
Best Momentum Stocks to Buy for January 6th
New Strong Buy Stocks for January 6th
Rigel Pharma: Formulating A Game Plan For 2026
Rigel Pharmaceuticals, Inc. $RIGL Position Boosted by Squarepoint Ops LLC
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of “Hold” from Analysts
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy?
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock?
Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue?
Rigel Pharma: Q3 Earnings Showcase Robust Growth
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
Eli Lilly Partner And Cancer Treatment Maker Nears Buy Point
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
Rigel to Present at the Jefferies Global Healthcare Conference in London
Surging Earnings Estimates Signal Upside for Rigel (RIGL) Stock
All You Need to Know About Rigel (RIGL) Rating Upgrade to Strong Buy
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates